High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group

N. Thielen; B. van der Holt; G.E.G. Verhoef; R.A.H.M. Ammerlaan; P. Sonneveld; J.J.W.M. Janssen; W. Deenik; J.H.F. Falkenburg; M.J. Kersten; H.A.M. Sinnige; M. Schipperus; A. Schattenberg; R.V. Kooy; W.M. Smit; I.W.T. Chu; P.J.M. Valk; G.J. Ossenkoppele; J.J. Cornelissen

doi:10.1007/s00277-013-1730-4

High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group

N. Thielen, B. van der Holt, G.E.G. Verhoef, R.A.H.M. Ammerlaan, P. Sonneveld, J.J.W.M. Janssen, W. Deenik, J.H.F. Falkenburg, M.J. Kersten, H.A.M. Sinnige, M. Schipperus, A. Schattenberg, R.V. Kooy, W.M. Smit, I.W.T. Chu, P.J.M. Valk, G.J. Ossenkoppele, J.J. Cornelissen

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	1049-1056
Journal	Annals of Hematology
Volume	92
Issue number	8
DOIs	https://doi.org/10.1007/s00277-013-1730-4
Publication status	Published - 2013

Access to Document

10.1007/s00277-013-1730-4

Cite this

Thielen, N., van der Holt, B., Verhoef, G. E. G., Ammerlaan, R. A. H. M., Sonneveld, P., Janssen, J. J. W. M., Deenik, W., Falkenburg, J. H. F., Kersten, M. J., Sinnige, H. A. M., Schipperus, M., Schattenberg, A., Kooy, R. V., Smit, W. M., Chu, I. W. T., Valk, P. J. M., Ossenkoppele, G. J., & Cornelissen, J. J. (2013). High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group. Annals of Hematology, 92(8), 1049-1056. https://doi.org/10.1007/s00277-013-1730-4

@article{5c0a61d2b99849569fd4d8960c2893ff,

title = "High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group",

author = "N. Thielen and {van der Holt}, B. and G.E.G. Verhoef and R.A.H.M. Ammerlaan and P. Sonneveld and J.J.W.M. Janssen and W. Deenik and J.H.F. Falkenburg and M.J. Kersten and H.A.M. Sinnige and M. Schipperus and A. Schattenberg and R.V. Kooy and W.M. Smit and I.W.T. Chu and P.J.M. Valk and G.J. Ossenkoppele and J.J. Cornelissen",

year = "2013",

doi = "10.1007/s00277-013-1730-4",

language = "Undefined/Unknown",

volume = "92",

pages = "1049--1056",

journal = "Annals of Hematology",

issn = "0939-5555",

publisher = "Springer Verlag",

number = "8",

}

Thielen, N, van der Holt, B, Verhoef, GEG, Ammerlaan, RAHM, Sonneveld, P, Janssen, JJWM, Deenik, W, Falkenburg, JHF, Kersten, MJ, Sinnige, HAM, Schipperus, M, Schattenberg, A, Kooy, RV, Smit, WM, Chu, IWT, Valk, PJM, Ossenkoppele, GJ & Cornelissen, JJ 2013, 'High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group', Annals of Hematology, vol. 92, no. 8, pp. 1049-1056. https://doi.org/10.1007/s00277-013-1730-4

High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group. / Thielen, N.; van der Holt, B.; Verhoef, G.E.G. et al.

In: Annals of Hematology, Vol. 92, No. 8, 2013, p. 1049-1056.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group

AU - Thielen, N.

AU - van der Holt, B.

AU - Verhoef, G.E.G.

AU - Ammerlaan, R.A.H.M.

AU - Sonneveld, P.

AU - Janssen, J.J.W.M.

AU - Deenik, W.

AU - Falkenburg, J.H.F.

AU - Kersten, M.J.

AU - Sinnige, H.A.M.

AU - Schipperus, M.

AU - Schattenberg, A.

AU - Kooy, R.V.

AU - Smit, W.M.

AU - Chu, I.W.T.

AU - Valk, P.J.M.

AU - Ossenkoppele, G.J.

AU - Cornelissen, J.J.

PY - 2013

Y1 - 2013

U2 - 10.1007/s00277-013-1730-4

DO - 10.1007/s00277-013-1730-4

M3 - Article

C2 - 23572137

VL - 92

SP - 1049

EP - 1056

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 8

ER -

Thielen N, van der Holt B, Verhoef GEG, Ammerlaan RAHM, Sonneveld P, Janssen JJWM et al. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group. Annals of Hematology. 2013;92(8):1049-1056. doi: 10.1007/s00277-013-1730-4